The new proactive approach and precision medicine in crohn's disease

15Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

The proactive approach to Crohn's disease (CD) management advocates moving toward algorithmic tight-control scenarios that are designed for each CD phenotype to guide remission induction, maintenance therapy, active monitoring, and multidisciplinary care to manage the complexities of each inflammatory bowel disease (IBD) patient. This requires accurate initial clinical, laboratory, radiological, endoscopic, and/or tissue diagnosis for proper phenotypic stratification of each CD patient. A substantial proportion of patients in symptomatic remission have been reported to demonstrate evidence of active disease, with elevated fecal calprotectin(FC) and C-reactive protein (CRP) levels as a hallmark for mucosal inflammation. Active mucosal inflammation, and elevated CRP and fecal calprotectin (FC) have been shown to be good predictors of clinical relapse, disease progression, and complications in IBD patients. The next frontier of treatment is personalized medicine or precision medicine to help solve the problem of IBD heterogeneity and variable responses to treatment. Personalized medicine has the potential to increase the efficacy and/or reduce potential adverse effects of treatment for each CD phenotype. However, there is currently an unmet need for better elucidation of the inflammatory biopathways and genetic signatures of each IBD phenotype, so personalized medicine can specifically target the underlying cause of the disease and provide maximal efficacy to each patient.

References Powered by Scopus

Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial

3922Citations
N/AReaders
Get full text

Infliximab, azathioprine, or combination therapy for Crohn's disease

2823Citations
N/AReaders
Get full text

The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications

2579Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease

47Citations
N/AReaders
Get full text

Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease

26Citations
N/AReaders
Get full text

Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zittan, E., Gralnek, I. M., & Berns, M. S. (2020, July 1). The new proactive approach and precision medicine in crohn’s disease. Biomedicines. MDPI AG. https://doi.org/10.3390/BIOMEDICINES8070193

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

57%

Researcher 3

21%

Lecturer / Post doc 2

14%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

60%

Agricultural and Biological Sciences 2

13%

Psychology 2

13%

Biochemistry, Genetics and Molecular Bi... 2

13%

Save time finding and organizing research with Mendeley

Sign up for free